drug
medroxyprogesterone acetate
Marketedupdated 3mo agoby Hong Kong King-Friend Pharmaceutical Co Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugDEPO-SUBQ PROVERA 104170 co-mentions · 57 sources
- drugDEPO-PROVERA170 co-mentions · 57 sources
- tagApproval110 co-mentions · 55 sources
- drugmedroxyprogesterone60 co-mentions · 57 sources
- companyEugia US LLC7 co-mentions · 2 sources
- tagRecall3 co-mentions · 2 sources
- companyEugia Pharma Specialties Ltd2 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 19 investigational indications.
all catalysts(55)
approval · 55
Oct 29, 1992
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Feb 17, 1994
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 1, 1994
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 1, 1994
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
May 3, 1995
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Nov 28, 1995
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Feb 1, 1996
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Mar 20, 1996
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 31, 1997
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Aug 12, 1998
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Apr 3, 2000
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jun 7, 2001
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Apr 26, 2002
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
May 23, 2002
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
May 23, 2003
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Nov 17, 2004
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 17, 2004
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
May 2, 2005
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Oct 28, 2005
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Nov 8, 2005
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Oct 5, 2007
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jul 15, 2009
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Oct 15, 2010
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jul 28, 2011
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Mar 25, 2013
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Sep 10, 2013
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Sep 27, 2013
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jun 9, 2014
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 23, 2015
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 23, 2015
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 30, 2015
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 30, 2015
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Feb 24, 2016
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Feb 29, 2016
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Aug 4, 2016
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Oct 14, 2016
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 16, 2016
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 16, 2016
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jan 31, 2017
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Mar 16, 2017
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Mar 1, 2018
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 23, 2019
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 23, 2019
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 23, 2019
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Sep 9, 2020
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Sep 9, 2020
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 4, 2020
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 4, 2020
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 4, 2020
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 4, 2020
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jul 11, 2024
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Jul 11, 2024
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 16, 2024
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 12, 2025
approval
$PFE28.24+3.63%
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 12, 2025
approval
$PFE28.24+3.63%
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Trials studying medroxyprogesterone acetate
- phase3Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
- phase2A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- phase4Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
- phase3Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
- phase4Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.
- phase2Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
- phase1Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that